16 completed, 3 no longer available, 3 terminated. 9 Phase 2, 9 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 7, Terminated 2 |
| Phase 3 | 9 | Completed 8, Terminated 1 |
| Phase 1 | 3 | Terminated 2, Completed 1 |
Follow Mesoblast, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC) Remestemcel-L, Placebo - Ulcerative Colitis | Phase 1 / Phase 2 | Terminated | The Cleveland Clinic | 7 | 2020-11-10 | 2026-04-16 |
| Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis Remestemcel-L, Placebo - Crohn Colitis | Phase 1 / Phase 2 | Terminated | The Cleveland Clinic | 7 | 2020-11-04 | 2026-04-16 |
| MSCs in COVID-19 ARDS Remestemcel-L, Placebo - Mesenchymal Stromal Cells, Remestemcel-L | Phase 3 | Terminated | Icahn School of Medicine at Mount Sinai | 223 | 2020-04-30 | 2022-04-25 |
| Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD Remestemcel-L - Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease | Phase 3 | Completed | Mesoblast, Inc. | 32 | 2015-10-28 | 2022-03-16 |
| A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD) remestemcel-L - Grade B aGVHD, Grade C aGVHD | Phase 3 | Completed | Mesoblast, Inc. | 55 | 2015-06-04 | 2022-03-17 |
| Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure Rexlemestrocel-L, Sham Comparator - Chronic Heart Failure | Phase 3 | Completed | Mesoblast, Inc. | 565 | 2014-03-03 | 2026-03-23 |
| Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction Placebo, Mesenchymal Precursor Cells (MPC) 12.5 M, Mesenchymal Precursor Cells (MPC) 25 M - Acute Myocardial Infarction | Phase 2 | Completed | Mesoblast, Inc. | 106 | 2013-03-11 | 2022-06-23 |
| Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease Prochymal® - Crohn's Disease | Phase 3 | Completed | Mesoblast, Inc. | 73 | 2010-11-29 | 2026-03-11 |
| Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI) Prochymal®, Placebo - Myocardial Infarction | Phase 2 | Completed | Mesoblast, Inc. | 220 | 2009-03-30 | 2026-03-11 |
| PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM) PROCHYMAL®, Placebo - Type 1 Diabetes Mellitus, Type 1 Diabetes | Phase 2 | Completed | Mesoblast, Inc. | 63 | 2008-06-11 | 2026-03-11 |
| PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Prochymal™, Placebo - Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema | Phase 2 | Completed | Mesoblast, Inc. | 62 | 2008-03-20 | 2026-03-11 |
| Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD) Prochymal®, Placebo, Corticosteroid - Graft Versus Host Disease | Phase 3 | Completed | Mesoblast, Inc. | 192 | 2008-01-31 | 2022-01-19 |
| Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease Prochymal®, Placebo - Crohn's Disease | Phase 3 | Completed | Mesoblast, Inc. | 330 | 2007-09-17 | 2026-03-11 |
| Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease Placebo, PROCHYMAL adult human mesenchymal stem cells - Crohn's Disease | Phase 3 | Completed | Mesoblast, Inc. | 98 | 2007-09-17 | 2026-03-11 |
| Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD) Prochymal®, Placebo, Standard of Care for GVHD - Graft Versus Host Disease | Phase 3 | Completed | Mesoblast, Inc. | 260 | 2006-08-17 | 2022-02-10 |
| Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease Prochymal™ adult human mesenchymal stem cells, adult human mesenchymal stem cells - Crohn's Disease | Phase 2 | Completed | Mesoblast, Inc. | 10 | 2006-03-13 | 2020-04-02 |
| Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants Prochymal - Graft Versus Host Disease | Phase 2 | Completed | Mesoblast, Inc. | 11 | 2005-11-18 | 2025-10-30 |
| Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD) Prochymal® - 2 Million cells/kg, Prochymal®- 8 Million cells/kg, Methylprednisolone - Graft Vs Host Disease | Phase 2 | Completed | Mesoblast, Inc. | 32 | 2005-04-27 | 2022-01-31 |
| Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction Provacel, Placebo - Myocardial Infarction | Phase 1 | Completed | Mesoblast, Inc. | 60 | 2005-03-22 | 2020-03-10 |
| Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD) Prochymal® - Graft-Versus-Host Disease | No longer available | Mesoblast, Inc. | 2020-03-09 |
Showing 20 of 22. Sign in to see all of them.
Crohn Disease (6) · Graft vs Host Disease (6) · Myocardial Infarction (3) · Bronchitis, Chronic (1) · Cardiovascular Diseases (1) · Colitis, Ulcerative (1) · Cytokine Release Syndrome (1) · Diabetes Mellitus, Type 1 (1) · Heart Failure (1) · Inflammation (1) · Insulin Resistance (1) · Leukemia (1) · Lymphoma (1) · Pulmonary Disease, Chronic Obstructive (1) · Pulmonary Emphysema (1)
remestemcel-l (18) · Methylprednisolone (2) · Prednisone (2) · Adrenal Cortex Hormones (1) · Cyclosporine (1) · Excipients (1) · Mycophenolic Acid (1) · Standard of Care (1) · Tacrolimus (1)
United States (21) · Canada (7) · Australia (4) · New Zealand (2) · Italy (1) · Switzerland (1) · United Kingdom (1)
Christopher James, PA (7) · Mahboob Rahman, MD (5) · Christopher James (2) · Ken Borow, MD (2) · Amy Lightner (1) · Amy Lightner, MD (1) · Annetine C Gelijns, PhD (1) · Eric Rose, MD (1) · Fred Grossman, DO (1) · Mahboob Rahman (1) · Michael Mack, MD (1) · Peter Smith, MD (1)
PMID 19539211, PMID 19958962, PMID 22292600, PMID 23172272, PMID 27515308, PMID 31318648, PMID 32018062, PMID 32044400, PMID 33964910